Overview Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Status: Withdrawn Trial end date: 2013-07-01 Target enrollment: Participant gender: Summary Open-label, pharmacodynamic, safety, pharmacokinetic and efficacy study of Lunacalcipol Injection. Phase: Phase 2 Details Lead Sponsor: OPKO Health, Inc.